Navigation Links
The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness"
Date:6/27/2008

NERVIANO, Italy, June 27 /PRNewswire/ --

- Accelera Recognised as Key Partner in the Development of a New Therapy

The development of fexinidazole for the treatment of African trypanosomiasis, commonly known as "sleeping sickness", by DNDi (Drugs for Neglected Diseases initiative), along with Accelera, a business unit of Nerviano Medical Sciences (NMS), is to be honoured as one of DNDi's Success Stories of the Year. The award will be conferred today in New York, at the prestigious headquarters of the New York Academy of Sciences, during the first annual Stakeholders' Meeting of DNDi. Accelera is recognised as DNDi's key partner in the non-clinical development of fexinidazole.

"We are proud to receive this recognition," comments Dr. Marco Brughera - Vice President of Accelera - "and happy to be able to contribute to improving the health of populations living in the poorest countries. We were delighted to be selected from among several international Contract Research Organisations (CROs) to be DNDi's partner of choice for characterizing the preclinical profile of fexinidazole"

"The preclinical work to support the profiling of fexinidazole started at Accelera more than one year ago," Dr Brughera points out "and included a series of in vitro and preliminary activities followed by a full package of tolerability and safety studies as requested by Regulatory Authorities. The results obtained have allowed DNDi to proceed to the next stage of fexinidazole's development, with a quick registration being a primary goal."

Accelera carries out preclinical development activities for molecules targeting various different therapeutic classes, including collaborations aimed at defining therapeutic solutions for other "neglected diseases," such as malaria, visceral leishmaniasis, African trypanosomiasis, and Chagas' disease.

"Our pride in this recognition is twofold: on the one hand there is the satisfaction of being an active collaborator within such international projects, and on the other the knowledge that we have been able to make our contribution to a humanitarian initiative like that of DNDi," continues Giampiero Duglio, Managing Director of NMS.

About Accelera (http://www.accelera.info)

Accelera, BU of Nerviano Medical Sciences, is a premium tier Contract Research Organization (CRO), working and collaborating with pharmaceutical and biotechnology companies around the world. Committed to offering the highest levels of service throughout drug discovery and development, our expertise can make a difference, right from the start.

About Nerviano Medical Sciences - NMS (http://www.nervianoms.com)

NMS is a research based company dedicated to the discovery and development of breakthrough new chemical entities (NCEs) for the treatment of cancer. NMS was incorporated in May 2004 as a spin-off from Pfizer and is wholly owned by the Rome-based Congregazione dei Figli dell'Immacolata Concezione (CFIC).

For further information please contact:

Accelera (Nerviano Medical Sciences)

Maria D'Acquino, mob +39-335-1863052

maria.d'acquino@nervianoms.com


'/>"/>
SOURCE Nerviano Medical Sciences (NMS): Accelera
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. QI projects may -- or may not -- improve patient safety and outcomes
2. MU researchers to collaborate on $20 million project
3. Fry Construction Selected for High-Profile Medical Imaging Project
4. Jacobs Receives Contract for New Hospital Project in Belgium
5. IVCC launches groundbreaking insecticide projects with Bayer and Syngenta
6. Global Health Project targets reducing AIDS among Indias adolescents
7. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
8. New Business Development of Multi-Hospital Project!
9. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
10. Meth Project Advertisements Selected for National Prevention Campaign
11. Pillow, PAs Great American Sleep Better(TM)Project Reports Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Sandbox, one of the nation’s ... in the newly created position of executive vice president, chief creative officer.     , ... the Chicago and LA offices. He reports to Nancy Finigan, president of those ...
(Date:5/3/2016)... ... ... Excessive panting in the car or cowering when new guests arrive are ... only manifests itself as trembling or ‘tail between the legs,’ but a pet ... about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn pet health products ...
(Date:5/3/2016)... Boston, MA (PRWEB) , ... May 03, 2016 , ... ... where clinicians can rehearse tough medical situations or practice tricky or rare procedures in ... Longwood Medical Area, the SIM Center is also available to inventors and “hackers” to ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... Ogawa ... with its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D ... massage. Starting each massage with a customized user profile and specialized massage program, each ...
(Date:5/3/2016)... ... May 03, 2016 , ... Octo Consulting ... and digital consulting services to the federal government, has been awarded a $9.9 ... Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive Office ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: ... today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in clinical ... track record, having supported the advancement of several products ... the United States and ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
Breaking Medicine Technology: